Graybug Vision Inc (GRAY): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRAY Stock Price Chart Interactive Chart >
GRAY Price/Volume Stats
| Current price | $5.87 | 52-week high | $37.88 |
| Prev. close | $5.53 | 52-week low | $3.43 |
| Day low | $5.00 | Volume | 24,035,400 |
| Day high | $6.97 | Avg. volume | 987,210 |
| 50-day MA | $4.53 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 123.60M |
Graybug Vision Inc (GRAY) Company Bio
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.
Latest GRAY News From Around the Web
Below are the latest news stories about Graybug Vision Inc that investors may wish to consider to help them evaluate GRAY as an investment opportunity.
Graybug Vision reports full data from mid-stage wet AMD trialGraybug Vision ([[GRAY]] -7.2%) has reported the results from full-data analysis of the Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD).Conducted across 33 sites in the U.S., the masked and controlled trial was designed to evaluate two doses of GB-102 with a single control... |
Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMDGraybug Vision Inc (NASDAQ: GRAY ) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet AMD). GB-102 is a proprietary formulation of sunitinib malate injected twice a year intravitreally. The ALTISSIMO full-data analysis focused on the GB-102 1mg arm compared to aflibercept and the pre-enrollment period, excluding results from the GB-102 2mg arm. Overall, GB-102 1mg was safe and well-tolerated. No drug-related serious adverse events or vision-threatening inflammation were reported. The … Full story available on Benzinga.com |
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate DevelopmentsREDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate developments and reported financial results for the quarter ended March 31, 2021. Recent Corporate Developments Full-data analysis from 12-month treatment phase of ALTISSIMO Phase 2b trial in wet AMD— GB-102 1mg has shown competitive durability and anatomical control versus aflibercept; trend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patients.Six-month observational trial extension of ALTISSIMO still underway— 14 of 28 patients enrolled have completed at least f... |
Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMDGB-102 1mg has shown competitive durability and anatomical control versus afliberceptTrend in mean BCVA of GB-102 1mg compared to aflibercept driven primarily by a subgroup of patientsDeveloping enhanced formulations and seeking partner funding for additional clinical trials of GB-102 Focus on advancing GB-401 implant for glaucoma Current cash sufficient to support planned operations into 2023 Management to host webcast/conference call today at 8 a.m. ET REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided full-data analysis from the 12-month treatment phase of its Phase 2b ALTISSIMO t... |
Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO TrialREDWOOD CITY, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced it will host a conference call and webcast to discuss the full-data analysis of the 12-month treatment phase of its Phase 2b ALTISSIMO trial on Wednesday, May 12, 2021 at 8 a.m. Eastern time (5 a.m. Pacific time). The event will be available live by dialing (844) 955-2748 (domestic) and (929) 517-0407 (international) and entering the conference ID# 5461708 or via webcast from the IR Events & Presentations page of the Investors and Media section of Graybug’s website at https://investors.graybug.vision/news-events/events-presentations... |
GRAY Price Returns
| 1-mo | 62.15% |
| 3-mo | -30.86% |
| 6-mo | -77.32% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -79.77% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...